Do the benefits of anti-arrhythmic drugs outweigh the associated risks? A tale of treatment goals in atrial fibrillation

Expert Review of Clinical Pharmacology

Volumn 5, Issue 2, 2012, Pages 163-171

  Kim, Michael H ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

anti arrhythmics; atrial fibrillation; comparative effectiveness; outcomes

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DOFETILIDE; DRONEDARONE; FLECAINIDE; PROPAFENONE; SOTALOL;

ANTICOAGULATION; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HOSPITALIZATION; HUMAN; QT PROLONGATION; QUALITY OF LIFE; REVIEW; SINUS RHYTHM; STROKE;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ELECTROCARDIOGRAPHY; EMBOLISM; HEART CONDUCTION SYSTEM; HEART FAILURE; HEART RATE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; STROKE; TREATMENT OUTCOME;

EID: 84863337892     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.12.5     Document Type: Review

References (59)

1. Miyasaka Y, Barnes ME, Gersh BJ et al. Secular trends in the incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114, 119-125 (2006).
2. Levy S, Maarek M, Coumel P et al.; on behalf of the college of French cardiologists. Characterization of different subsets of atrial fibrillation in general practice in France. Circulation 99, 3028-3035 (1999).
3. Van Gelder IC, Hemels MEW. The progressive nature of atrial fibrillation: A rationale for early restoration and maintenance of sinus rhythm. Europace 8, 943-949 (2006).
4. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999. Circulation 108, 711-716 (2003).
5. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham heart study. Circulation 98, 946-952 (1998).
6. Reynolds MR, Essebag V, Zimetbaum P, Cohen DJ. Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: The FRACTAL registry. J. Cardiovasc. Electrophysiol. 18, 628-633 (2007).
7. Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 9, 348-356 (2006).
8. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ. Cardiovasc. Qual. Outcomes 4, 313-320 (2011).
9. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med. 329, 673-682 (1993).
10. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet 361, 13-20 (2003).
11. Andersen HR, Nielsen TT, Rasmussen K et al.; for the DANAMI-2 Investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N. Engl. J. Med. 349, 733-742 (2003).
12. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N. Engl. J. Med. 321, 406-412 (1989).
13. Haissaguerre M, Jais P, Shah DC et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N. Engl. J. Med. 339, 659-666 (1998).
14. Wann LS, Curtis AB, January CT et al.; writing on behalf of the 2006 ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation writing committee. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J. Am. Coll. Cardiol. 57, 223-242 (2011).
15. Gillis AM, Verma A, Talajic M, Nattel S, Dorian P. Canadian cardiovascular society atrial fibrillation guidelines 2010: Rate and rhythm management. Can. J. Cardiol. 27, 47-59 (2011).
16. Camm AJ, Kirchhof P, Lip GY et al.; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur. Heart J. 31(19), 2369-2429 (2010).
17. Kim MH, Lin J, Hussein M, Battleman D. The incidence and economic burden of suspected adverse events and adverse event monitoring during atrial fibrillation therapy. Curr. Med. Res. Opin. 25(12), 3037-3047 (2009).
18. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Mahe I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: A systematic review of randomized controlled trials. Arch. Intern. Med. 166, 719-728 (2006).
19. Kim MH, Klingman D, Lin J, Battleman DS. Patterns and predictors of discontinuation of rhythm-control therapy in patients with newly diagnosed atrial fibrillation. Pharmacotheraphy 29(12), 1417-1426 (2009).
20. Kim MH, Smith PJ, Jhaveri M, Lin J, Klingman D. One year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: A retrospective claims database analysis. Clin. Ther. 33(11), 1668-1681 (2011).
21. The AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: An AFFIRM substudy of the first antiarrhythmic drug. J. Am. Coll. Cardiol. 42, 20-29 (2003).
22. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The DIONYSOS study. J. Cardiovasc. Electrophysiol. 21, 597-605 (2010).
23. Roy D, Talajic M, Dorian P et al.; for the Canadian Trial of Atrial Fibrillation Investigators. Amiodarone to prevent recurrence of atrial fibrillation. N. Engl. J. Med. 342, 913-920 (2000).
24. Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace 13(3), 329-345 (2011).
25. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: A meta-analysis. J. Am. Coll. Cardiol. 30, 791-798 (1997).
26. Andersen SS, Hansen ML, Gislason GH et al. Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: A nationwide study. Europace 11, 886-891 (2009).
27. Reiffel JA, Kowey PR, Myerburg R et al. Practice patterns among United States cardiologists for managing adults with atrial fibrillation (from the AFFECTS Registry). Am. J. Cardiol. 105, 1122-1129 (2010).
28. Kober L, Torp-Pedersen C, McMurray JJV et al.; Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N. Engl. J. Med. 358, 2678-2687 (2008).
29. Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. 352, 225-237 (2005).
30. Roy D, Talajic M, Nattel S et al.; the Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N. Engl. J. Med. 358, 2667-2677 (2008).
31. Kirchhof P, Auricchio A, Bax J et al. Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German atrial fibrillation competence network and the European heart rhythm association. Europace 9, 1006-1023 (2007).
32. Allessie M, Ausma J, Schotten U. Electrical, contractile, and structural remodeling during atrial fibrillation. Cardiovasc. Res. 54, 230-246 (2002).
33. Sherman DG, Kim SG, Boop BS et al.; for NHLBI AFFIRM investigators. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-Up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch. Intern. Med. 165, 1185-1191 (2005).
34. Ezekowitz MD, Aikens TH, Nagarakanti R, Shapiro T. Atrial fibrillation: outpatient presentation and management. Circulation 124, 95-99 (2011).
35. Wyse DG, Waldo AL, DiMarco JP et al.; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. 347, 1825-1833 (2002).
36. Corley SD, Epstein AE, DiMarco JP et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Circulation 109(12), 1509-1513 (2004).
37. Saksena S, Slee A, Waldo AL et al. Cardiovascular outcomes in the AFFIRM trial: An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses. J. Am. Coll. Cardiol. 58, 1975-1985 (2011).
38. Hohnloser SH, Crijins HJ, van Eickels M et al.; for ATHENA investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med. 360, 668-678 (2009).
39. Singh BN, Connolly SJ, Crijins HJ et al.; for the EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N. Engl. J. Med. 357, 987-999 (2007).
40. Page RL, Connolly SJ, Crijins HJ et al.; for the ATHENA investigators. Rhythm and rate controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). Am. J. Cardiol. 107, 1019-1022 (2011).
41. Joghetaei N, Weirich G, Huber W, Buchler P, Estner H. Acute liver failure associated with dronedarone. Circ. Arrhythm. Electrophysiol. 4, 592-593 (2011).
42. Connolly SJ, Camm AJ, Halperin JL et al.; PALLAS investigators. Dronedarone in high-risk permanent atrial fibrillation. N. Engl. J. Med. 365, 2268-2276 (2011).
43. Duray GZ, Torp-Pedersen C, Connolly SJ, Hohnloser SH. Effects of dronedarone on clinical outcomes in patients with lone atrial fibrillation: pooled post hoc analysis from the ATHENA/EURIDIS/ADONIS studies. J. Cardiovasc. Electrophysiol. 22(7), 770-776 (2011).
44. Marshall DA, Levy AR, Vidaillet H et al. Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Ann. Intern. Med. 141, 653-661 (2004).
45. Pietrasik A, Kosior DA, Niewada M, Opolski G, Latek M, Kaminski B. The cost comparison of rhythm and rate control strategies in persistent atrial fibrillation. Int. J. Cardiol. 118, 21-27 (2007).
46. Fenwick E, Marshall DA, Levy AR, Nichol G. Using and interpreting cost-effectiveness acceptability curves: An example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv. Res. 6, 52 (2006).
47. Gutierrez C, Blanchard DG. Atrial fibrillation: Diagnosis and treatment. Am. Fam. Physician 83, 61-68 (2011).
48. Terasawa T, Balk EM, Chung M et al. Systematic review: Comparative effectiveness of radiofrequency catheter ablation for atrial fibrillation. Ann. Intern. Med. 151, 191-202 (2009).
49. Nair GM, Nery PB, Diwakaramenon S, Healey JS, Connolly SJ, Morillo CA. A systematic review of randomized trials comparing radiofrequency ablation with antiarrhythmic medications in patients with atrial fibrillation. J. Cardiovasc. Electrophysiol. 20, 138-144 (2009).
50. Calkins H, Reynolds MR, Spector P et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: Two systematic literature reviews and meta-analyses. Circ. Arrhythmia Electrophysiol. 2, 349-361 (2009).
51. Weerasooriya R, Khairy P, Litalien J et al. Catheter ablation for atrial fibrillation: Are results maintained at 5 years of follow-up? J. Am. Coll. Cardiol. 57, 160-166 (2011).
52. Cappato R, Calkins H, Chen SA et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 111, 1100-1105 (2005).
53. Cappato R, Calkins H, Chen SA et al. Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J. Am. Coll. Cardiol. 53, 1798-1803 (2009).
54. Cleland JGF, Coletta AP, Buga L, Ahmed D, Clark AL. Clinical trials update from the American College of Cardiology meeting 2010: DOSE, ASPIRE, CONNECT, STICH, STOP-AF, CABANA, RACE II, EVEREST II, ACCORD, and NAVIGATOR. Eur. J. Heart Failure 12, 623-629 (2010).
55. Huxley RR, Lopez FL, Folsom AR et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: The Atherosclerosis Risk in Communities (ARIC) study. Circulation 123, 1501-1508 (2011).
56. Hohnloser SH, Kuck KH, Lilienthal J; for the PIAF Investigators. Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial. Lancet 356, 1789-1794 (2000).
57. Van Gelder IC, Hagens VE, Bosker HA et al.; for the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med. 347, 1834-1840 (2002).
58. Carlsson J, Miketic S, Windeler J et al.; for the STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) study. J. Am. Coll. Cardiol. 41, 1690-1696 (2003).
59. Opolski G, Torbicki A, Kosior DA et al.; for the Investigators of the Polish HOT CAFE Trial. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: The results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) study. Chest 126, 476-486 (2004).